CClinicalTrials.gg
WithdrawnNCT03256149SHDDUpdated Dec 14, 2022

High Dose Steroids for Dysphagia

An interventional study of Dexamethasone and Placebo in Dysphagia and Cervical Spine Disease, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Withdrawn at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-14.

Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Not applicable, Interventional, and Prevention

Why this study was withdrawn
Not enough patients recruted
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Few existing data currently indicates that anti-inflammatory drugs could help diminish the local cervical inflammation tough to cause the dysphagia, hoarseness and dyspnea after an anterior surgical approach to the spine. This study aims to evaluate the effect of high dose of steroids on dysphagia after an anterior cervical spine procedure. Patients subjected to a cervical spine surgery through an anterior approach will be randomized to a treatment group receiving 3 doses of IV dexamethasone (decadron) and a placebo group receiving saline. Outcome will be measured with dysphagia scales, modified barium swallow and rhino-pharyngo-laryngoscopy, all done pre and post-operatively. Secondary outcomes involve neurological condition, pain and fusion rate.

02

Conditions studied

  • Dysphagia
  • Cervical Spine Disease
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Anterior cervical spine surgery
  • Elective surgery

Exclusion criteria

Exclusion Criteria:

  • Takes steroids for any reason
  • Pre-existing condition leading to dysphagia
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Treatment group

    Dexamethasone, 4 mg IV given at 8 hours interval, first dose received at the time of surgery (induction), 3 doses total

    Drug: Dexamethasone

  • Placebo comparator
    Placebo group

    Saline given at 8 hours interval, first dose received at the time of surgery (induction), 3 doses total

    Drug: Placebo

Interventions

  • DrugDexamethasone

    Also known as: Decradron

  • DrugPlacebo

    Normal saline (IV placebo)

    Also known as: Saline

05

What researchers measure

Primary outcomes

  1. Voice evaluation

    Voice handicap index

    Time frame: First day post-operatively

  2. Dysphagia evaluation: MBSimp

    Modified Barium Swallow with the calculation fof the MBSimp score

    Time frame: First day post-operatively

  3. Soft tissue edema

    Pre-vertebral soft tissue edema on X Ray

    Time frame: First day post-operatively

  4. Airway evaluation

    Rhino-Pharyngo-Laryngoscopy

    Time frame: First day post-operatively

  5. Dysphagia evaluation: Rosenbeck

    Modified Barium Swallow with calculation of the Rosenbeck score

    Time frame: First day post-operatively

Secondary outcomes

  1. Hyperreflexia

    hyperreflexia assesment using osteotendinous reflexes graded on a 1 to 4 scale

    Time frame: 3 months post-operatively

  2. Fusion rate

    Cervical spine fusion at site of surgery seen on CT scan

    Time frame: 6 months after surgery

  3. Pain

    Subjective neck pain using analog pain scale

    Time frame: 3 months after surgery

  4. Strenght

    4 limbs strengh assessment on a 0 to 5 scale

    Time frame: 3 months after surgery

  5. Crude touch sensation

    Presence or absence of hypoesthesia in the limbs

    Time frame: 3 months after surgery

  6. Surgical site infection

    Presence or absence of superficial or deep surgical site infection

    Time frame: 3 months after surgery

06

Study locations

1 site
  • Centre Hospitalier de l'Université de Montréal (CHUM)
    Montreal, Quebec H2L4M1, Canada
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03256149
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Responsible party
Sponsor
First posted
Aug 21, 2017
Start date
Mar 24, 2015
Primary completion
Nov 2018 (estimated)
Completion
Feb 2019 (estimated)
Last update
Dec 14, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion